Angiotensin‐converting enzyme inhibitors vs placebo
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
1 finding from 1 review
- Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes onlyRR 1.33 [1.26, 1.41]2 studies · 8873 participantsLow